Nairametrics
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Content Partners
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Get Data
    • Macro-Economic News
    • Research Analysis
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
No Result
View All Result
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Content Partners
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Get Data
    • Macro-Economic News
    • Research Analysis
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
No Result
View All Result
Nairametrics
No Result
View All Result
Home Business News Coronavirus

Guillain-Barre syndrome listed as ‘very rare’ side effect of AstraZeneca vaccine

Chidinma Anyalewechi by Chidinma Anyalewechi
September 10, 2021
in Coronavirus
Guillain-Barre syndrome listed as ‘very rare’ side effect of AstraZeneca vaccine
Share on FacebookShare on TwitterShare on Linkedin

The neurological disorder, Guillain-Barre syndrome, which can cause temporary paralysis, has been listed as a “very rare” side effect of the AstraZeneca COVID-19 vaccine by the European Medicines Agency.

The Guillain-Barre syndrome disorder is a nerve inflammation that could cause temporary paralysis and difficulty in breathing.

This was made known in an EMA update on Wednesday. The update stated that a causal relationship was “considered at least a reasonable possibility”.

RelatedPosts

FG says Nigeria gathering vaccine producers to develop technology in case of future outbreaks

You can now go to United States without COVID-19 tests

This comes after a total of 833 cases of the syndrome had been reported worldwide by July 31, from about 592 million doses of the AstraZeneca “Vaxzevria” shot administered.

The EMA has maintained that the Guillain-Barre syndrome should be added to the product information as a side effect of Vaxzevria, even though the syndrome is a “very rare” side effect, and only occurs under one in 10,000 people.

According to the agency, a warning should be added to the information on the vaccine which informs people to seek medical attention if they feel symptoms and develop weakness or paralysis that can affect the chest and face.

In July, the EMA had listed Guillain-Barre syndrome as a “very rare” side effect of the Johnson & Johnson vaccine, which uses the same adenovirus technology as the AstraZeneca vaccine. The US Food and Drug Administration had also warned in July of an increased risk of developing the neurological syndrome with Johnson & Johnson’s dose.

Despite this, EMA and US Food and Drug Administration have continued to stress that the vaccine’s benefits outweigh the potential risks.

Related

Tags: AstraZeneca COVID-19 vaccineEuropean Medicines AgencyGuillain-Barre syndrome

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Hot forex
Cornerstone
Mega Millions
Polaris Bank
Access Bank
Bankers Committee
First bank


FCMB
Ikeja Electrics




    Business News | Stock Market | Money Market | Cryptos | Financial Literacy | SME |

    Recent News

    • Bulls are back: Nigerian stock market gains N8 billion
    • Why court awarded Nigerian musician N20 million in damages against MTN, others
    • Dangote Cement appoints Dr. Gbenga Fapohunda as Acting Group Chief Finance Officer

    Follow us on social media:

    Recent News

    Nigerian stock market dips 0.57% as investors part with N117 billion

    Bulls are back: Nigerian stock market gains N8 billion

    June 30, 2022
    Federal Government Vs Petro Union: $15 billion case resumes today

    Why court awarded Nigerian musician N20 million in damages against MTN, others

    June 30, 2022
    • ABOUT US
    • CONTACT US
    • PRODUCTS
    • ANDROID APP
    • iOS APP
    • DISCLAIMER
    • CAREERS
    • PRIVACY POLICY

    © 2022 Nairametrics

    No Result
    View All Result
    • Home
    • Exclusives
      • Financial Analysis
      • Corporate Stories
      • Interviews
      • Investigations
      • Metrics
    • Markets
      • Cryptos
      • Commodities
      • Equities
        • Dividends
        • Stock Market
      • Fixed Income
      • Market Views
      • Securities
    • Industries
      • Company News
      • Consumer Goods
      • Content Partners
      • Corporate deals
      • Corporate Press Releases
      • Energy
      • Entertainment
      • Financial Services
      • Hospitality & Travel
      • Manufacturing
      • Real Estate and Construction
      • Tech News
    • Economy
      • Get Data
      • Macro-Economic News
      • Research Analysis
    • Business News
    • Financial Literacy
      • Career tips
      • Personal Finance
    • Lifestyle
      • Billionaire Watch
      • Profiles
    • Opinions
      • Blurb
      • Op-Eds

    © 2022 Nairametrics

    Social Media Auto Publish Powered By : XYZScripts.com